Against the background of the strong heterogenic distribution of sIL-6R levels with mean levels of 76 ng/ml in synovial fluid of RA patients (21), the treatment failure of some patients treated with JAKi could be explained by effects of remaining local high levels of IL-1β affecting RASF. The gene discussed is IL1B; the disease is rheumatoid arthritis.